Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) have received a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $8.00.

A number of analysts have recently issued reports on the company. Roth Mkm reaffirmed a “buy” rating and set a $10.00 target price on shares of Gain Therapeutics in a research report on Friday, December 19th. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Gain Therapeutics in a research note on Friday, December 19th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Gain Therapeutics in a report on Monday, December 29th.

Institutional Trading of Gain Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Millennium Management LLC acquired a new stake in Gain Therapeutics in the fourth quarter valued at $45,000. Engineers Gate Manager LP bought a new stake in shares of Gain Therapeutics in the 4th quarter worth about $47,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Gain Therapeutics in the 4th quarter worth about $120,000. Marshall Wace LLP raised its stake in shares of Gain Therapeutics by 849.3% in the 4th quarter. Marshall Wace LLP now owns 1,662,293 shares of the company’s stock valued at $5,353,000 after purchasing an additional 1,487,186 shares in the last quarter. Finally, State Street Corp raised its stake in shares of Gain Therapeutics by 72.9% in the 4th quarter. State Street Corp now owns 157,537 shares of the company’s stock valued at $507,000 after purchasing an additional 66,400 shares in the last quarter. Institutional investors own 11.97% of the company’s stock.

Gain Therapeutics Stock Performance

NASDAQ:GANX opened at $1.95 on Wednesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.52 and a quick ratio of 2.52. The firm has a 50-day moving average of $2.15 and a two-hundred day moving average of $2.37. The stock has a market cap of $75.00 million, a P/E ratio of -3.20 and a beta of -0.03. Gain Therapeutics has a 1-year low of $1.41 and a 1-year high of $4.34.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.